Abstract
Cerebral venous thrombosis (CVT) causes significant disability and mortality. Current guidelines for CVT management support the initial use of unfractionated heparin or low molecular weight heparin followed by longer-term oral vitamin K antagonist (VKA). There has been increasing, albeit limited, evidence for the use of direct oral anticoagulants (DOAC) as an alternative to VKA. We performed a systematic review and meta-analysis of studies that compared the safety and efficacy of DOACs to VKA in treating CVT. A comprehensive literature search was carried out in Medline, Embase and Cochrane Stroke Group Trials Register using a suitable keyword/MeSH term search strategy. All studies published in English comparing outcomes of patients with CVT treated with DOAC or VKA were included. In total, 6 studies (5 observational studies and 1 randomized clinical trial) comprising 412 patients (age range 16–83 years) were analyzed. DOAC was used in 151 patients, while 261 received VKA. The follow-up period was 3–11 months. The efficacy of DOACs was comparable with VKA in terms of partial or full thrombus recanalization (RR 1.02, 95% CI 0.89–1.16) and excellent functional recovery with modified Rankin scale < 2 (RR 1.02, 95% CI 0.93–1.13). Patients treated with DOAC developed lower major bleeding events when compared to VKA, although this did not reach statistical significance (RR 0.44, 95% CI 0.12–1.59). We provide preliminary evidence to support DOAC as effective and safe alternatives to VKA in CVT treatment. We await the results of upcoming randomized trials to further support our results and validate the use of DOAC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tadi P BB, Baruffi S (2020) Cerebral venous thrombosis. [Updated 2019 Nov 23]. StatPearls. StatPearls Publishing, Treasure Island, FL. https://www.ncbi.nlm.nih.gov/books/NBK459315/.
Saposnik G, Barinagarrementeria F, Brown RD Jr et al (2011) Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(4):1158–1192
Mekaj YH, Mekaj AY, Duci SB, Miftari EI (2015) New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 11:967–977
Ferro JM, Coutinho JM, Dentali F et al (2019) Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 76:1457–1465
Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
Wells GA SB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. https://www.ohrica/programs/clinical_epidemiology/oxfordasp.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):7s–47s
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352
Leow AS, Sia CH, Tan BY, Loh JP (2018) A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus. J Thromb Thrombolysis 46(1):68–73
Field T (2019) Multicentre PROL, blinded-endpoint (PROBE) controlled trial of early anticoagulation with rivaroxaban versus standard of care in determining safety at 365 days in symptomatic cerebral venous thrombosis. NCT03178864 CgI.
Lurkin A, Derex L, Fambrini A et al (2019) Direct oral anticoagulants for the treatment of cerebral venous thrombosis. Cerebrovasc Dis 48(1–2):32–37
Wasay M, Khan M, Rajput HM et al (2019) New oral anticoagulants versus warfarin for cerebral venous thrombosis: a multi-center, observational study. J Stroke 21(2):220–223
Geisbusch C, Richter D, Herweh C, Ringleb PA, Nagel S (2014) Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients. Stroke 45(8):2469–2471
Herweh C, Griebe M, Geisbusch C et al (2016) Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. Eur J Neurol 23(4):681–687
Wells J, Ehrlich M, Johansen M, Rahman S, Chapman S, Worrall B, Chiota-McCollum N (2019) Novel Oral Anticoagulants (NOACs) vs. Warfarin in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): a retrospective study of functional and radiographic outcomes among patients enrolled in BEAST (Biorepository to Establish the Aetiology of Sinovenous Thrombosis) at UVA. Neurology. https://doi.org/10.1212/WNL.8.5.311
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors declare any conflicts of interest or competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lee, G.K.H., Chen, V.H., Tan, CH. et al. Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis. J Thromb Thrombolysis 50, 724–731 (2020). https://doi.org/10.1007/s11239-020-02106-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-020-02106-7